BACKGROUND: Patients with atopic dermatitis (AD) are prone to disseminated viral skin infections and therefore are not vaccinated against smallpox because of potential complications. Macrophage inflammatory protein 3alpha (MIP-3alpha) is a C-C chemokine expressed by keratinocytes that exhibits antimicrobial activity against bacteria and fungi; however, its role in antiviral innate immunity is unknown. OBJECTIVE: Evaluate the level of MIP-3alpha in AD skin and its role in the innate immune response to vaccinia virus (VV). METHODS: Macrophage inflammatory protein 3alpha levels were evaluated using real-time RT-PCR, immunodot-blot, and immunohistochemistry. The antiviral activity of MIP-3alpha was determined using a standard viral plaque assay. RESULTS: Macrophage inflammatory protein 3alpha gene expression was significantly (P < .01) decreased in AD skin (0.21 +/- 0.05 ng MIP-3alpha/ng glyceraldehyde-3-phosphate dehydrogenase) compared with psoriasis skin (0.67 +/- 0.13). This was confirmed at the protein level using immunohistochemistry. We further demonstrate that T(H)2 cytokines downregulate MIP-3alpha expression. The importance of MIP-3alpha in the innate immune response against VV was established by first demonstrating that MIP-3alpha exhibits activity against VV. Second, VV replication was significantly increased (P < .01) in keratinocytes treated with an antibody to neutralize MIP-3alpha. CONCLUSION: The current study demonstrates that MIP-3alpha exhibits antiviral activity against VV and demonstrates the importance of MIP-3alpha in the innate immune response against VV. In addition, AD skin is deficient in MIP-3alpha, in part because of the overexpression of T(H)2 cytokines in AD skin. CLINICAL IMPLICATIONS: MIP-3alpha deficiency in AD skin contributes to patients' increased propensity toward eczema vaccinatum. Increasing MIP-3alpha or neutralizing T(H)2 cytokines could prevent adverse reactions in patients with AD after smallpox vaccination.
BACKGROUND: Patients with atopic dermatitis (AD) are prone to disseminated viral skin infections and therefore are not vaccinated against smallpox because of potential complications. Macrophage inflammatory protein 3alpha (MIP-3alpha) is a C-C chemokine expressed by keratinocytes that exhibits antimicrobial activity against bacteria and fungi; however, its role in antiviral innate immunity is unknown. OBJECTIVE: Evaluate the level of MIP-3alpha in AD skin and its role in the innate immune response to vaccinia virus (VV). METHODS: Macrophage inflammatory protein 3alpha levels were evaluated using real-time RT-PCR, immunodot-blot, and immunohistochemistry. The antiviral activity of MIP-3alpha was determined using a standard viral plaque assay. RESULTS: Macrophage inflammatory protein 3alpha gene expression was significantly (P < .01) decreased in AD skin (0.21 +/- 0.05 ng MIP-3alpha/ng glyceraldehyde-3-phosphate dehydrogenase) compared with psoriasis skin (0.67 +/- 0.13). This was confirmed at the protein level using immunohistochemistry. We further demonstrate that T(H)2 cytokines downregulate MIP-3alpha expression. The importance of MIP-3alpha in the innate immune response against VV was established by first demonstrating that MIP-3alpha exhibits activity against VV. Second, VV replication was significantly increased (P < .01) in keratinocytes treated with an antibody to neutralize MIP-3alpha. CONCLUSION: The current study demonstrates that MIP-3alpha exhibits antiviral activity against VV and demonstrates the importance of MIP-3alpha in the innate immune response against VV. In addition, AD skin is deficient in MIP-3alpha, in part because of the overexpression of T(H)2 cytokines in AD skin. CLINICAL IMPLICATIONS: MIP-3alpha deficiency in AD skin contributes to patients' increased propensity toward eczema vaccinatum. Increasing MIP-3alpha or neutralizing T(H)2 cytokines could prevent adverse reactions in patients with AD after smallpox vaccination.
Authors: Alice Y Liu; Delphine Destoumieux; Annie V Wong; Christina H Park; Erika V Valore; Lide Liu; Tomas Ganz Journal: J Invest Dermatol Date: 2002-02 Impact factor: 8.551
Authors: T Nakayama; R Fujisawa; H Yamada; T Horikawa; H Kawasaki; K Hieshima; D Izawa; S Fujiie; T Tezuka; O Yoshie Journal: Int Immunol Date: 2001-01 Impact factor: 4.823
Authors: Peck Y Ong; Takaaki Ohtake; Corinne Brandt; Ian Strickland; Mark Boguniewicz; Tomas Ganz; Richard L Gallo; Donald Y M Leung Journal: N Engl J Med Date: 2002-10-10 Impact factor: 91.245
Authors: B Homey; M C Dieu-Nosjean; A Wiesenborn; C Massacrier; J J Pin; E Oldham; D Catron; M E Buchanan; A Müller; R deWaal Malefyt; G Deng; R Orozco; T Ruzicka; P Lehmann; S Lebecque; C Caux; A Zlotnik Journal: J Immunol Date: 2000-06-15 Impact factor: 5.422
Authors: Ichiro Nomura; Elena Goleva; Michael D Howell; Quatyba A Hamid; Peck Y Ong; Clifton F Hall; Marc A Darst; Bifeng Gao; Mark Boguniewicz; Jeffrey B Travers; Donald Y M Leung Journal: J Immunol Date: 2003-09-15 Impact factor: 5.422
Authors: M C Dieu-Nosjean; C Massacrier; B Homey; B Vanbervliet; J J Pin; A Vicari; S Lebecque; C Dezutter-Dambuyant; D Schmitt; A Zlotnik; C Caux Journal: J Exp Med Date: 2000-09-04 Impact factor: 14.307
Authors: Carlos F Santillan Salas; Sonia Mehra; Maria R Pardo Crespo; Young J Juhn Journal: Allergy Asthma Proc Date: 2013 Sep-Oct Impact factor: 2.587
Authors: Mardi A Crane-Godreau; Matthew A Maccani; Susan K Eszterhas; Sandra L Warner; James A Jukosky; Steven Fiering Journal: Open Immunol J Date: 2009-01-01
Authors: Emma Guttman-Yassky; Michelle A Lowes; Judilyn Fuentes-Duculan; Lisa C Zaba; Irma Cardinale; Kristine E Nograles; Artemis Khatcherian; Inna Novitskaya; John A Carucci; Reuven Bergman; James G Krueger Journal: J Immunol Date: 2008-11-15 Impact factor: 5.422
Authors: Lisa A Beck; Mark Boguniewicz; Tissa Hata; Lynda C Schneider; Jon Hanifin; Rich Gallo; Amy S Paller; Susi Lieff; Jamie Reese; Daniel Zaccaro; Henry Milgrom; Kathleen C Barnes; Donald Y M Leung Journal: J Allergy Clin Immunol Date: 2009-06-27 Impact factor: 10.793
Authors: Mimi Ghosh; Zheng Shen; Todd M Schaefer; John V Fahey; Phalguni Gupta; Charles R Wira Journal: Am J Reprod Immunol Date: 2009-07 Impact factor: 3.886